Press release content from Globe Newswire. The AP news staff was not involved in its creation. Claritas (Formerly Kalytera Therapeutics) Cites Breakthrough Data by Massachusetts General ... Claritas Pharmaceuticals, Inc.March 2, 2021 GMT SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the “Company” or “Claritas”) today announced that compelling data demonstrating that nitric oxide achieved viral clearance in severe and critical COVID-19 patients validates the potential of the Company’s proprietary nitric oxide releasing compound, R-107, as a therapy for coronavirus and COVID-19 infection. Breakthrough Data with Nitric Oxide in COVID-19